Condition: GLP - 1 · Sponsor: University of Massachusetts, Worcester
The goal of this project is to study how well the Noom digital lifestyle program works for adults who are taking Glucagon-Like Peptide-1 receptor agonist (GLP-1) medications. The study team will assess how the program affects people's behaviors and health outcomes. The team will also look at how digital lifestyle change interventions can be implemented in real-world settings, including how many people it reaches, how well it is put into practice, whether people stick with it over time, and whether it works well for different groups of people.
This description comes directly from the study's public registry record.
Reem Y Najjar, BS · 774-275-0890 · Reem.Najjar@umassmed.edu
Joann Wagner, MSW · 508-856-6944 · joann.wagner@umassmed.edu
Always discuss trial participation with your own doctor first.
| UMass Chan Medical School - Shaw Building | Worcester, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07481305